



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 27 Mar 2017 (#12)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date. The application will be submitted two (2) days before the application due date.**

## Important notices

- Notice of Correction to Funds Available for PAR-16-115 "Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01)" ([NOT-AI-17-020](#)) National Institute of Allergy and Infectious Diseases
- [NIH Statement on World Tuberculosis Day](#)

### 1. Integration and Validation of Emerging Technologies to Accelerate Cancer Research

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-CA-17-023\)](#)

**Type:** R33

**Application Due Date:** May 10, 2017 apply by 5:00 PM local time of applicant organization.

**This Funding Opportunity Announcement (FOA)** is associated with the [Beau Biden Cancer Moonshot<sup>SM</sup> Initiative](#) that is intended to accelerate cancer research. The purpose of this FOA is to promote research on the advanced development and rigorous validation of new enabling technologies/tools/capabilities with a transformative potential for cancer research and clinical oncology. Specifically, this FOA targets the following four areas designated as scientific priorities:

- Enhanced experimental and analytical capabilities addressing complexities of cancer development;
- New capabilities advancing precise clinical diagnosis of cancer patients;
- Novel predictive *ex vivo* and/or *in silico* modeling approaches; and
- New technologies/approaches to improve biospecimen and data quality.

Applications must be focused on one of these areas and must be based on comprehensive preliminary data substantiating the potential of the proposed technologies/tools/capabilities and the functionality their contributing components. Essential aspect is a rigorous technical validation to ensure that the transformative, enabling potential of the proposed technologies/tools/capabilities for cancer research and/or clinical care is thoroughly verified by the end of the project period.

**Budget:** NIH intends to fund up to 10 awards, corresponding to a total of \$5,000,000, for fiscal year 2017. Future year amounts will depend on annual appropriations. Direct costs are limited to \$325,000 per year. Application budgets must reflect actual needs of the proposed project. The total project period may not exceed 3 years.

### 2. Advancing the Science of Geriatric Palliative Care

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-17-225\)](#)  
[\(PA-17-226\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) apply by 5:00 PM local time of applicant organization.

**This Funding Opportunity Announcement (FOA)** encourages research grant applications focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 3. Hearing Health Care for Adults: Improving Access and Affordability

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-17-227\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#) and apply by 5:00 PM local time of applicant organization.

**This Funding Opportunity Announcement (FOA)** encourages exploratory and developmental research applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults.

**Budget:** Direct Costs maximum of \$275,000 over two years with no more than \$200,000 direct costs in either year. The maximum project period is 2 years.

### 4. Human-Animal Interaction (HAI) Research

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-17-231\)](#)

**Type:** R01

[\(PAR-17-229\)](#)

R21

[\(PAR-17-230\)](#)

R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization.

**This Funding Opportunity Announcement (FOA)** invites grant applications for research to examine 1) the impact of HAI on typical and atypical child development and health; 2) the evaluation of animal-assisted intervention for children and adults with disabilities or in need of rehabilitative services; 3) the effects of animals on public health, including cost effectiveness of involving animals in reducing and preventing disease.

**Budget: R01:** Budgets are limited to \$499,999 Direct Costs per year. Application budgets should reflect the actual needs of the proposed project. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R03:** No more than \$50,000 in direct costs may be requested in any single year. The total project period may not exceed 2 years.



**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**D71 - International Research Training Planning Grant:** To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

**D43 - International Research Training Grants:** To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

**R01 - NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 - NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 - NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

**R25 - NIH Education Projects:** used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

**R34 - Clinical Trial Planning Grant Program:** To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

**R35 - Outstanding Investigator Award:** To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

**U01 - NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U24 - Resource-Related Research Projects - Cooperative Agreements:** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

**U01 - NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U19 - Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.